SCHEMBL2730164

SCHEMBL2730164

CCOC(=O)c1[nH]c2ccccc2c1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.63
HTR6 P50406 2/20 0.63
TUBB4A P04350 2/20 0.61
TUBB P07437 2/20 0.61
TUBA3C P0DPH7 2/20 0.61
TUBA1B P68363 2/20 0.61
TUBA4A P68366 2/20 0.61
TUBB4B P68371 2/20 0.61
TUBB3 Q13509 2/20 0.61
TUBB2A Q13885 2/20 0.61
TUBB8 Q3ZCM7 2/20 0.61
TUBA3E Q6PEY2 2/20 0.61
TUBA1A Q71U36 2/20 0.61
TUBA1C Q9BQE3 2/20 0.61
TUBB6 Q9BUF5 2/20 0.61
TUBB2B Q9BVA1 2/20 0.61
TUBB1 Q9H4B7 2/20 0.61
ALDH1A1 P00352 6/20 0.60
HPGD P15428 5/20 0.60
TSHR P16473 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103611 0.90 KDM4E (0.59) KDM4EHTR6TUBB4ATUBBTUBA3C
SCHEMBL2880010 0.84 KDM4E (0.66) KDM4EHTR6TUBB4ATUBBTUBA3C
SCHEMBL3276393 0.83 TUBB4A (0.67) KDM4EHTR6TUBB4ATUBBTUBA3C
SCHEMBL7534562 0.83 ALDH1A1 (0.71) KDM4EHTR6TUBB4ATUBBTUBA3C
SCHEMBL2730310 0.83 NR4A2 (0.62) KDM4ETUBB4ATUBBTUBA3CTUBA1B
SCHEMBL8689527 0.82 ALDH1A1 (0.69) KDM4ETUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3029308 0.82 ALOX15 (0.74) ALDH1A1HPGDCYP1A2XBP1CYP2C19
SCHEMBL43369 0.82 KDM4E (0.63) KDM4EHTR6TUBB4ATUBBTUBA3C
SCHEMBL4740841 0.82 KDM4E (0.63) KDM4EHTR6TUBB4ATUBBTUBA3C
SCHEMBL4332747 0.82 KDM4E (0.70) KDM4EHTR6TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
EP-4259635-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2023-10-18 EP disclosed
CN-116829560-A Oxytocin receptor modulators 金奥克斯治疗有限公司 2023-09-29 CN disclosed
WO-2022126179-A1 OXYTOCIN RECEPTOR MODULATORS THE UNIVERSITY OF SYDNEY (AU) 2022-06-23 WO disclosed
WO-2022126179-A1 OXYTOCIN RECEPTOR MODULATORS THE UNIVERSITY OF SYDNEY (AU) 2022-06-23 WO disclosed
EP-2635567-B1 INDOLE DERIVATIVES RICHTER GEDEON NYRT (HU) 2015-10-28 EP disclosed
CN-104649854-A Cheap and efficient preparation method of aryl halides UNIV BEIJING 2015-05-27 CN disclosed
EP-1451185-B1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2014-08-06 EP disclosed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed
US-6337344-B1 ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-08 US disclosed
US-6288103-B1 MONOCYTE CHEMOATTRACTANT PROTEINS ANTAGONIST SUCH AS N-(3-CHLOROPHENYLSULPHONYL)INDOLE-2-CARBOXYLIC ACID; ANTIINFLAMMATORY AGENTS ZENECA LIMITED (GB) 2001-09-11 US disclosed
EP-1042287-A1 INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA Aventis Pharma Deutschland GmbH (DE) 2000-10-11 EP disclosed
EP-1003504-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS AstraZeneca UK Limited (GB) 2000-05-31 EP disclosed
EP-1001935-A1 INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS ZENECA LIMITED (GB) 2000-05-24 EP disclosed
WO-1999033800-A1 INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-07-08 WO disclosed
WO-1999007678-A1 INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 WO disclosed
WO-1999007351-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 KDM4E 1608/4885HTR6 325/4885TUBB4A 182/4885
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS OXTR, AVPR1B, AVPR1A KDM4E 4374/4885HTR6 218/4885TUBB4A 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.